GENE ONLINE|News &
Opinion
Blog

2025-04-30|

Asembia Summit: IRA Drug Negotiation to Reshape Medicare Part B and Commercial Healthcare Delivery

by Mark Chiang
Share To

NEWSFLASH

Panelists at Asembia’s AXS25 Summit discussed the Inflation Reduction Act’s (IRA) drug negotiation provisions, highlighting their potential to significantly alter Medicare drug pricing, provider reimbursement, and healthcare delivery models within both Part B and commercial markets. The discussions at the summit suggest the IRA’s drug negotiation measures will likely have a ripple effect. Specifically, the panelists noted the law’s impact will extend beyond just drug costs. They expect it to reshape how Medicare Part B providers are reimbursed and influence the overall structure of healthcare delivery in both the Medicare system and the broader commercial healthcare landscape.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
LATEST
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
SURMOUNT-5 Trial: Zepbound Shows Greater Weight Loss Than Wegovy
2025-05-14
ASCGT Meeting Navigates Biotech Downturn After Multi-Year Slump
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top